Treatment of Acrodermatitis continua of Hallopeau with Ixekizumab.

We present a patient with ACH resistant to multiple therapies, including the biologic adalimumab, who was successfully treated with an IL-17 inhibitor (Ixekizumab). We believe our unique treatment with an excellent outcome may assist other dermatologists if faced with this condition.
PMID: 31184530 [PubMed - as supplied by publisher]

Source: Journal of Dermatological Treatment - June 13, 2019 Category: Dermatology Tags: J Dermatolog Treat Source Type: research